Acrux Nets US$550K Divesting Prilocaine/Lidocaine Cream Rights

Strategic Portfolio Review

Acrux Limited, the Australian drug delivery company, has announced the divestment of the US registration and distribution rights for its Prilocaine 2.5% and Lidocaine 2.5% cream. This move follows a comprehensive review of its topical generic drug portfolio, which identified several products with growing revenue streams, such as Nitroglycerine 0.4% ointment and Dapsone gels, while highlighting the cream as no longer materially contributing to overall portfolio performance.

Details of the Divestment

The rights to the Prilocaine/Lidocaine cream in the United States have been sold to Acrux’s distributor for US$550,000, with proceeds expected to be received by the end of December 2025. While the announcement does not disclose the identity of the acquiring distributor or the impact on Acrux’s revenue, the divestment signals a clear strategic shift to streamline the company’s assets and focus on more promising products.

Focus on Hormone Replacement Therapy

Importantly, Acrux has earmarked the proceeds from this sale to support the continued development of its Hormone Replacement Therapy (HRT) products. HRT represents a growing segment within the pharmaceutical space, addressing a significant patient need with potential for robust market growth. This reinvestment underscores Acrux’s commitment to innovation and patient-preferred healthcare solutions.

Implications for Investors

For investors, this divestment reflects Acrux’s active portfolio management approach, prioritizing assets that deliver stronger returns and growth potential. While the immediate financial impact is modest, the strategic reallocation of capital towards HRT development could enhance long-term value. Market watchers will be keen to monitor upcoming updates on the progress of these therapies and any further portfolio adjustments.